Antonio B. Ward
Antonio B. Ward has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Adam B. Keeton
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
3 shared publications - Gary Anthony Piazza
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
3 shared publications - Yulia Y. Maxuitenko
Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
3 shared publications - Donald J. Buchsbaum
Department of Obstetrics and Gynecology, University of Alabama at Birmingham
2 shared publications - Michael R. Boyd
ADT Pharmaceuticals LLC, Orange Beach, Alabama
2 shared publications - Tyler E. Mattox
University of South Alabama, Mobile, Alabama
2 shared publications
Latest Publications
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eadt9565
Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models
Clinical efficacy with chimeric antigen receptor (CAR) T cells is currently limited by numerous factors including poor initial product phenotypes and lack of engagement of endogenous immunity. Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide, and the antagonism of its receptor (VIPR) on T cells potentiates T cell activation. We demonstrated that VIP suppresses CAR T cell function and engineered CAR T cells to secrete a short peptide drug that antagonizes VIPR (CAR/VIPRa). Armored CAR/VIPRa T cells maintained a memory phenotype and were metabolically quiescent after manufacturing yet mounted a strong bioenergetic response after antigen stimulation. Moreover, CAR/VIPRa T cells potentiated endogenous antitumor immunity through the recruitment of host T cells. In syngeneic and xenogeneic mouse models of hematological and solid tumors, CAR/VIPRa T cells exhibited greater tumor infiltration and maintained a less exhausted memory phenotype, resulting in superior antitumor efficacy. Together, these data show that VIPRa peptides produced by armored CAR T cells can enhance T cell function and boost endogenous immunity, thereby improving tumor control.
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eadt9565
Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models
Clinical efficacy with chimeric antigen receptor (CAR) T cells is currently limited by numerous factors including poor initial product phenotypes and lack of engagement of endogenous immunity. Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide, and the antagonism of its receptor (VIPR) on T cells potentiates T cell activation. We demonstrated that VIP suppresses CAR T cell function and engineered CAR T cells to secrete a short peptide drug that antagonizes VIPR (CAR/VIPRa). Armored CAR/VIPRa T cells maintained a memory phenotype and were metabolically quiescent after manufacturing yet mounted a strong bioenergetic response after antigen stimulation. Moreover, CAR/VIPRa T cells potentiated endogenous antitumor immunity through the recruitment of host T cells. In syngeneic and xenogeneic mouse models of hematological and solid tumors, CAR/VIPRa T cells exhibited greater tumor infiltration and maintained a less exhausted memory phenotype, resulting in superior antitumor efficacy. Together, these data show that VIPRa peptides produced by armored CAR T cells can enhance T cell function and boost endogenous immunity, thereby improving tumor control.
- 19 December 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (5) , 956-972
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Activated RAS is a common driver of cancer that was considered undruggable for decades. Recent advances have enabled the development of RAS inhibitors, but the efficacy of these inhibitors remains limited by resistance. In this study, we developed a pan-RAS inhibitor, ADT-007, (Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide, that binds nucleotide-free RAS to block GTP activation of effector interactions and MAPK/AKT signaling, resulting in mitotic arrest and apoptosis. ADT-007 potently inhibited the growth of RAS-mutant cancer cells irrespective of the RAS mutation or isozyme. Wild-type RAS (RASWT) cancer cells with GTP-activated RAS from upstream mutations were equally sensitive. Conversely, RASWT cancer cells harboring downstream BRAF mutations and normal cells were essentially insensitive to ADT-007. Sensitivity of cancer cells to ADT-007 required activated RAS and dependence on RAS for proliferation, whereas insensitivity was attributed to metabolic deactivation by UDP-glucuronosyltransferases that were expressed in RASWT and normal cells but repressed in RAS-mutant cancer cells. ADT-007 displayed unique advantages over KRAS mutant-specific, pan-KRAS, and pan-RAS inhibitors that could impact in vivo antitumor efficacy by escaping compensatory mechanisms that lead to resistance. Local administration of ADT-007 showed robust antitumor activity in syngeneic immunocompetent and xenogeneic immune-deficient mouse models of colorectal and pancreatic cancers. The antitumor activity of ADT-007 was associated with the suppression of MAPK signaling and activation of innate and adaptive immunity in the tumor immune microenvironment. Oral administration of ADT-007 prodrug also inhibited tumor growth. Thus, ADT-007 has the potential to address the complex RAS mutational landscape of many human cancers and to improve treatment of RAS-driven tumors. Significance: ADT-007, a first-in-class pan-RAS inhibitor, has unique selectivity for cancer cells with mutant RAS or activated RAS protein and the capability to circumvent resistance to suppress tumor growth, supporting further development of ADT-007 analogs.
- 19 December 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (5) , 956-972
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Activated RAS is a common driver of cancer that was considered undruggable for decades. Recent advances have enabled the development of RAS inhibitors, but the efficacy of these inhibitors remains limited by resistance. In this study, we developed a pan-RAS inhibitor, ADT-007, (Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide, that binds nucleotide-free RAS to block GTP activation of effector interactions and MAPK/AKT signaling, resulting in mitotic arrest and apoptosis. ADT-007 potently inhibited the growth of RAS-mutant cancer cells irrespective of the RAS mutation or isozyme. Wild-type RAS (RASWT) cancer cells with GTP-activated RAS from upstream mutations were equally sensitive. Conversely, RASWT cancer cells harboring downstream BRAF mutations and normal cells were essentially insensitive to ADT-007. Sensitivity of cancer cells to ADT-007 required activated RAS and dependence on RAS for proliferation, whereas insensitivity was attributed to metabolic deactivation by UDP-glucuronosyltransferases that were expressed in RASWT and normal cells but repressed in RAS-mutant cancer cells. ADT-007 displayed unique advantages over KRAS mutant-specific, pan-KRAS, and pan-RAS inhibitors that could impact in vivo antitumor efficacy by escaping compensatory mechanisms that lead to resistance. Local administration of ADT-007 showed robust antitumor activity in syngeneic immunocompetent and xenogeneic immune-deficient mouse models of colorectal and pancreatic cancers. The antitumor activity of ADT-007 was associated with the suppression of MAPK signaling and activation of innate and adaptive immunity in the tumor immune microenvironment. Oral administration of ADT-007 prodrug also inhibited tumor growth. Thus, ADT-007 has the potential to address the complex RAS mutational landscape of many human cancers and to improve treatment of RAS-driven tumors. Significance: ADT-007, a first-in-class pan-RAS inhibitor, has unique selectivity for cancer cells with mutant RAS or activated RAS protein and the capability to circumvent resistance to suppress tumor growth, supporting further development of ADT-007 analogs.
- Open Access
- 1 January 2020
- Published by KEAI Publishing in Oncology Signaling
- Vol. 3, 1-6
Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity
- 1 January 2020
- Published by KEAI Publishing in Oncology Signaling
- Vol. 3, 1-6
Open AccessTargeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity
- 1 July 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (13_Supplem) , 2707
Abstract 2707: A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity
Approximately 45% of colorectal cancers harbor mutations in the KRAS gene, resulting in constitutive activation of RAS signaling through effector proteins, primarily RAF and PI3K. Members of the RAS family are GTPases that function as a molecular switch, cycling between inactive (GDP-bound) and active (GTP-bound) states in cells to regulate proliferation and survival. Constitutive signaling from mutant RAS drives tumorigenesis, in part, by deregulation of the cell cycle, resulting in increased proliferation (mitosis) and decreased apoptosis of tumor cells. From an extensive medicinal chemistry/screening campaign, we identified a novel compound class that potently and selectively inhibits the growth of tumor cell lines harboring constitutively activated RAS by a mechanism involving the disruption of RAS nucleotide loading, blockage of effector activation, and consequent inhibition of signaling. A prototype of the class, MCI-062, inhibits the growth of KRAS-driven (HCT-116) colon tumor cells with low nanomolar IC50 values, while RAS-independent (HT-29) colon tumor cells harboring the BRAF V600E mutation, are essentially insensitive. A strong correlation was measured among a larger panel of tumor cell lines between potency to inhibit tumor cell growth and levels of activated RAS. The growth inhibitory effects of MCI-062 were sustained and irreversible as demonstrated by colony formation and apoptosis assays. MCI-062 treatment of HCT-116 colon tumor cells reduced levels of activated RAS and RAS-mediated signaling as measured by GST-RBD pulldown assays and phospho-specific immunoblotting. Within the same concentration range, MCI-062 induced mitotic arrest as measured by cell cycle analysis of DNA content and phospho-histone H3B immunofluorescence. Further analysis revealed that MCI-062 interfered with localization of the mitosis-inducing protein, PLK1 to kinetochores and decreased nuclear localization of its substrate, Cdc25C, a downstream target of RAS-RAF signaling involved in both mitotic entry and exit checkpoints. In vivo testing of MCI-062 in a syngeneic mouse model of KRAS-driven colon cancer (CT-26) demonstrated that MCI-062 engages its molecular target, depleting GTP-RAS and suppressing activation of the MAPK signal transduction pathway, and inhibiting tumor growth. MCI-062 also suppresses PD-L1 expression and activates anti-tumor immunity, which may contribute to its antitumor activity and suggests potential benefits of combining with immunotherapy. From these studies, we have identified a novel class of RAS inhibitors that potently and selectively inhibits RAS-driven tumor growth by disrupting downstream signaling, leading to cell cycle arrest and apoptosis. These findings support further development of MCI-062 for treatment of RAS-driven colorectal and other cancers. Funding provided by NCI grants R01CA131378, R01CA148817, R01CA197147, and R01CA155638. Citation Format: Adam B. Keeton, Antonio Ward, Xi Chen, Jacob Valiyaveettil, Bing Zhu, Veronica Ramirez-Alcantara, Yulia Maxuitenko, Kristy Berry, Tyler E. Mattox, Michael R. Boyd, Gary A. Piazza. A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2707.
- 1 July 2019
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (13_Supplem) , 2707
Abstract 2707: A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity
Approximately 45% of colorectal cancers harbor mutations in the KRAS gene, resulting in constitutive activation of RAS signaling through effector proteins, primarily RAF and PI3K. Members of the RAS family are GTPases that function as a molecular switch, cycling between inactive (GDP-bound) and active (GTP-bound) states in cells to regulate proliferation and survival. Constitutive signaling from mutant RAS drives tumorigenesis, in part, by deregulation of the cell cycle, resulting in increased proliferation (mitosis) and decreased apoptosis of tumor cells. From an extensive medicinal chemistry/screening campaign, we identified a novel compound class that potently and selectively inhibits the growth of tumor cell lines harboring constitutively activated RAS by a mechanism involving the disruption of RAS nucleotide loading, blockage of effector activation, and consequent inhibition of signaling. A prototype of the class, MCI-062, inhibits the growth of KRAS-driven (HCT-116) colon tumor cells with low nanomolar IC50 values, while RAS-independent (HT-29) colon tumor cells harboring the BRAF V600E mutation, are essentially insensitive. A strong correlation was measured among a larger panel of tumor cell lines between potency to inhibit tumor cell growth and levels of activated RAS. The growth inhibitory effects of MCI-062 were sustained and irreversible as demonstrated by colony formation and apoptosis assays. MCI-062 treatment of HCT-116 colon tumor cells reduced levels of activated RAS and RAS-mediated signaling as measured by GST-RBD pulldown assays and phospho-specific immunoblotting. Within the same concentration range, MCI-062 induced mitotic arrest as measured by cell cycle analysis of DNA content and phospho-histone H3B immunofluorescence. Further analysis revealed that MCI-062 interfered with localization of the mitosis-inducing protein, PLK1 to kinetochores and decreased nuclear localization of its substrate, Cdc25C, a downstream target of RAS-RAF signaling involved in both mitotic entry and exit checkpoints. In vivo testing of MCI-062 in a syngeneic mouse model of KRAS-driven colon cancer (CT-26) demonstrated that MCI-062 engages its molecular target, depleting GTP-RAS and suppressing activation of the MAPK signal transduction pathway, and inhibiting tumor growth. MCI-062 also suppresses PD-L1 expression and activates anti-tumor immunity, which may contribute to its antitumor activity and suggests potential benefits of combining with immunotherapy. From these studies, we have identified a novel class of RAS inhibitors that potently and selectively inhibits RAS-driven tumor growth by disrupting downstream signaling, leading to cell cycle arrest and apoptosis. These findings support further development of MCI-062 for treatment of RAS-driven colorectal and other cancers. Funding provided by NCI grants R01CA131378, R01CA148817, R01CA197147, and R01CA155638. Citation Format: Adam B. Keeton, Antonio Ward, Xi Chen, Jacob Valiyaveettil, Bing Zhu, Veronica Ramirez-Alcantara, Yulia Maxuitenko, Kristy Berry, Tyler E. Mattox, Michael R. Boyd, Gary A. Piazza. A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2707.
- 12 June 2013
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 135 (1) , 193-201
Induction of Endocannabinoid Levels in Juvenile Rat Brain Following Developmental Chlorpyrifos Exposure
The endogenous cannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) play vital roles during nervous system development. The degradation of 2-AG and AEA is mediated by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. These enzymes are inhibited following developmental chlorpyrifos (CPF) exposure. To investigate whether this inhibition is persistent or whether accumulation of endocannabinoids in the brain occurs, 10-day-old rat pups were orally exposed daily for 7 days to either corn oil or increasing dosages of CPF (1, 2.5, or 5mg/kg), and forebrains were collected at 4, 12, 24, and 48h following the last administration. All dosages inhibited cholinesterase (ChE), FAAH, and MAGL, and elevated AEA and 2-AG levels with the greatest effect occurring at 12h with ChE, FAAH, AEA, and 2-AG and at 4h with MAGL. With the high dosage, return to control levels occurred with 2-AG (48h) only. With the medium dosage, return to control levels occurred with MAGL, 2-AG, and AEA (48h) but not with ChE or FAAH. With the low dosage, return to control levels occurred with MAGL (12h), ChE and 2-AG (24h), and AEA (48h) but not with FAAH. With the lowest dosage, peak inhibition of FAAH (52%) is greater than that of ChE (24%) and that level of FAAH inhibition is sufficient to induce a persistent pattern of elevated AEA. It is possible that this pattern of elevation could alter the appropriate development of neuronal brain circuits.
- 12 June 2013
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 135 (1) , 193-201
Induction of Endocannabinoid Levels in Juvenile Rat Brain Following Developmental Chlorpyrifos Exposure
The endogenous cannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) play vital roles during nervous system development. The degradation of 2-AG and AEA is mediated by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. These enzymes are inhibited following developmental chlorpyrifos (CPF) exposure. To investigate whether this inhibition is persistent or whether accumulation of endocannabinoids in the brain occurs, 10-day-old rat pups were orally exposed daily for 7 days to either corn oil or increasing dosages of CPF (1, 2.5, or 5mg/kg), and forebrains were collected at 4, 12, 24, and 48h following the last administration. All dosages inhibited cholinesterase (ChE), FAAH, and MAGL, and elevated AEA and 2-AG levels with the greatest effect occurring at 12h with ChE, FAAH, AEA, and 2-AG and at 4h with MAGL. With the high dosage, return to control levels occurred with 2-AG (48h) only. With the medium dosage, return to control levels occurred with MAGL, 2-AG, and AEA (48h) but not with ChE or FAAH. With the low dosage, return to control levels occurred with MAGL (12h), ChE and 2-AG (24h), and AEA (48h) but not with FAAH. With the lowest dosage, peak inhibition of FAAH (52%) is greater than that of ChE (24%) and that level of FAAH inhibition is sufficient to induce a persistent pattern of elevated AEA. It is possible that this pattern of elevation could alter the appropriate development of neuronal brain circuits.